Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Acquisitions & Divestments: 2012-2017

Historic Change in Acquisitions & Divestments for Ocular Therapeutix (OCUL) over the last 4 years, with Dec 2017 value amounting to $38.2 million.

  • Ocular Therapeutix's Change in Acquisitions & Divestments fell 79.57% to $3.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $54.2 million, marking a year-over-year decrease of 31.98%. This contributed to the annual value of $38.2 million for FY2017, which is 52.65% down from last year.
  • Ocular Therapeutix's Change in Acquisitions & Divestments amounted to $38.2 million in FY2017, which was down 52.65% from $80.7 million recorded in FY2016.
  • Ocular Therapeutix's Change in Acquisitions & Divestments' 5-year high stood at $80.7 million during FY2016, with a 5-year trough of $38.2 million in FY2017.
  • For the 3-year period, Ocular Therapeutix's Change in Acquisitions & Divestments averaged around $57.9 million, with its median value being $54.8 million (2015).
  • In the last 5 years, Ocular Therapeutix's Change in Acquisitions & Divestments spiked by 47.16% in 2016 and then slumped by 52.65% in 2017.
  • Over the past 3 years, Ocular Therapeutix's Change in Acquisitions & Divestments (Yearly) stood at $54.8 million in 2015, then soared by 47.16% to $80.7 million in 2016, then tumbled by 52.65% to $38.2 million in 2017.